Survodutide 10mg

A dual agonist of the GLP-1 and glucagon receptors developed by Boehringer Ingelheim. The GLP-1 action reduces appetite and improves blood-sugar control; the glucagon action increases energy expenditure and pulls fat out of the liver. In Phase 2 trials it produced up to about 19% weight loss at 46 weeks, and a separate trial in MASH — fatty liver disease with inflammation — showed improvement in liver fat and scarring in most participants. It is in Phase 3 trials for obesity and liver disease.